ISPOR Europe Research Poster:

Comparing Factors Influencing Price Elasticity of Pharmaceuticals and Value-Based Pricing Across Europe and the USA

Authors: Michelle James, Kimrin Pannu, Clare Foy, Calum Jones, Helena Grant, Araadhna Sinha, Adam Brown

Presenter: Adam Brown

Presentation Time: Tuesday 19th November, 10.30am–1.30pm

In this short video, Michelle James (Consultant – Market Access) talks us through the research:

Request a copy of our poster:

Complete the form to request a copy of our research poster.

    Keep me up to date with the latest news and events.

    References for our poster:

    1. Anderson P, McLellan RD, Overton JP, Wolfram GL. Price Elasticity of Demand: Harvard University; 1997. Available from: https://scholar.harvard.edu/files/alada/files/price_elasticity_of_demand_handout.pdf. Accessed: October 2024.
    2. Lu YC, Fu DJ, An D, Chiu A, Schwartz R, Nikitin AY, et al. Scalable Production and Cryostorage of Organoids Using Core-Shell Decoupled Hydrogel Capsules. Advanced biosystems. 2017;1(12).
    3. Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017;55(2):191-198.
    4. von der Schulenburg F, Vandoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Economics Review. 2011;1(1):18.
    5. Gemmil M, editor. The price elasticity of demand for prescription drugs: An exploration of demand in different settings. 2008. Available from: https://etheses.lse.ac.uk/2944/1/U615895.pdf. Accessed: October 2024.
    6. Gatwood J, Gibson TB, Chernew ME, Farr AM, Vogtmann E, Fendrick AM. Price elasticity and medication use: cost sharing across multiple clinical conditions. J Manag Care Spec Pharm. 2014;20(11):1102-7.
    7. Yeung K, Basu A, Hansen RN, Sullivan SD. Price elasticities of pharmaceuticals in a value based-formulary setting. Health Economics. 2018;27(11):1788-804.
    8. Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77(3):251-77.
    9. Hernández-Izquierdo C, González López-Valcárcel B, Morris S, Melnychuk M, Abásolo Alessón I. The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand. PLoS ONE. 2019;14(3):e0213403.
    10. Campbell J, Roibu C, Ivanova H, Macaulay R. PHP60 – PAYER ARCHETYPING – EXPANDING HORIZONS. Value in Health. 2018;21:S160.
    11. Foxon G. What are Payer archetypes and why are they important. 2020. Available from: https://remapconsulting.com/training/what-are-payer-archetypes-and-why-are-they-important/. Accessed: October 2024.
    12. Pretium Strategy. The European Market Access Challenge: From Complexity to Clarity. 2023. Available from: https://pretiumstrategy.com/articles/f/the-european-market-access-challenge-from-complexity-to-clarity. Accessed: October 2024.
    13. Jørgensen J, Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J Mark Access Health Policy. 2015;3.
    14. Conic F, Buente M, Hosseini M. The shift toward regulated drug pricing. 2024. Available from: https://www.rolandberger.com/en/Insights/Publications/US-pharmaceutical-pricing-at-a-crossroads.html#:~:text=The%20pharmaceutical%20market%20in%20the,package%20signed%20off%20in%202022. Accessed: October 2024.
    15. Vokinger KN, Naci H. Negotiating Drug Prices in the US—Lessons From Europe. JAMA Health Forum. 2022;3(12):e224801-e.
    16. Hwang TJ, Kesselheim AS, Rome BN. New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges. JAMA. 2022;328(11):1041-2.
    17. Tribble S. KFF Health News. 2018. Available from: https://kffhealthnews.org/news/u-s-market-for-biologic-drugs-is-most-expensive-in-the-world/#:~:text=Now%2C%20the%20U.S.%20government%20stops,U.S.%20or%20gaining%20market%20share. Accessed: October 2024.
    18. OECD. Pharmaceutical Spending. n.d. Available from: https://www.oecd.org/en/data/indicators/pharmaceutical-spending.html?oecdcontrol-0ad85c6bab-var1=DEU%7CGBR. Accessed: October 2024.
    19. Moss RJ, Batista A, Makridaki D, Süle A, Kohl S. Procurement. Eur J Hosp Pharm. 2019;26(3):173-4.
    20. Roediger A, Wilsdon T, Haderi A, Pendleton K, Azais B. Competition between on-patent medicines in Europe. Health Policy. 2019;123(7):652-60.
    21. Kang SY, Bai G, DiStefano MJ, Socal MP, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. Annu Rev Public Health. 2020;41:499-512.
    22. McClellan C, Fingar KR, Ali MM, Olesiuk WJ, Mutter R, Gibson TB. Price elasticity of demand for buprenorphine/naloxone prescriptions. J Subst Abuse Treat. 2019;106:4-11.
    23. Carl DL, Laube Y, Serra-Burriel M, Naci H, Ludwig WD, Vokinger KN. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland. JAMA Netw Open. 2022;5(12):e2244670-e.
    24. Chhabra H, Mouslim MC, Kashiramka S, Rathore AS. Dynamics of biosimilar uptake in emerging markets. Expert Opin Biol Ther. 2022;22(6):679-88.
    25. Varghese MS, Liu CL, Kazi DS. The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. Curr Cardiol Rep. 2021;23(11):163.
    26. Mardetko N, Nabergoj Makovec U, Locatelli I, Janez A, Kos M. Uptake of new antidiabetic medicines in 11 European countries. BMC Endocrine Disorders. 2021;21(1):127.
    27. Spicer O, Grootendorst P. The effect of patented drug price on the share of new medicines across OECD countries. Health Policy. 2022;126(8):795-801.
    28. Brekke KR, Dalen DM, Straume OR. Paying for pharmaceuticals: uniform pricing versus two-part tariffs. J Health Econ. 2022;83:102613.
    29. Barbier L, Vandenplas Y, Boone N, Huys I, Janknegt R, Vulto AG. How to select a best-value biological medicine? A practical model to support hospital pharmacists. Am J Health Syst Pharm. 2022;79(22):2001-11.
    30. Messori A. Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship. Sci Pharm. 2015;84(1):73-9.
    31. Messori A. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy. Clin Drug Investig. 2016;36(8):599-603.
    32. Mendoza RL. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics. J Med Econ. 2020;23(9):915-22.
    33. Sarpatwari A, DiBello J, Zakarian M, Najafzadeh M, Kesselheim AS. Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Med. 2019;16(7):e1002872.
    34. Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, et al. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. BioDrugs. 2021;35(2):187-99.
    35. Maksabedian Hernandez EJ, Graf M, Portelli A, Shafrin J. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. J Med Econ. 2022;25(1):1118-26.
    36. Foxon G. What are Payer archetypes and why are they important. 2020. Available from: https://remapconsulting.com/training/what-are-payer-archetypes-and-why-are-they-important/. Accessed: October 2024.
    37. Jommi C, Bertolani A, Armeni P, Costa F, Otto M. Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe. Health Policy and Technology. 2023;12(3):100771.
    38. Privolnev Y, Albacker C, Nasa M. PBI26 SINK OR SWIM: HOW CAN SLE BIOLOGICS SUCCESSFULLY ACHIEVE OPTIMAL REIMBURSEMENT AND UPTAKE IN THE EU5? Value in Health. 2019;22:S51-S2.
    39. Thokala P, Carlson JJ, Drummond M. HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales. J Managed Care Spec Pharm. 2020;26(9):1162-70.
    40. Field R. Comparative Effectiveness Research and Health Reform in the USA. In: Levy A, Sobolev B, editors. Comparative Effectiveness Research in Health Services. Boston, MA: Springer US. 2016;41-55.
    41. Mondelo-García C, Mendoza E, Movilla-Fernández M-J, Coronado C. Perceptions of pharmacists and physicians on generic substitution in a financial crisis context in Northwestern Spain: A qualitative study. Health Policy. 2018;122(12):1316-25.
    42. Bhattacharya J, Vogt WB. A Simple Model of Pharmaceutical Price Dynamics. The Journal of Law and Economics. 2003;46(2):599-626.
    43. Directorate-general for internal policies. Differences in costs of and access to pharmaceutical products in the EU. In: Policy PDEaS, editor. 2011.

     

    Return to our ISPOR Europe virtual booth